Given that the PARP inhibitors niraparib and rucaparib are currently approved for the maintenance of HR proficient cancers, PRMT5 inhibition may represent a combination to expand the utility of PARP inhibition to earlier lines of therapy. This evidence concerns the gene PARP1 and cancer.